$ポセイダ セラピューティクス(PSTX.US)$ NEWS Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
$ポセイダ セラピューティクス(PSTX.US)$ NEWS Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
Dr. Rizvi's appointment, with his vast experience in cancer treatments, is a major asset to Poseida Therapeutics. His expertise will be crucial as the company progresses its clinical stage CAR-T portfolio.
Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.
ポセイダ セラピューティクスに関するコメント
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
まだコメントはありません